-
公开(公告)号:CA2892045A1
公开(公告)日:2014-05-30
申请号:CA2892045
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC , PTC THERAPEUTICS INC
Inventor: LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D471/04
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-
2.
公开(公告)号:WO2014081906A3
公开(公告)日:2014-07-17
申请号:PCT/US2013071132
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D239/48
CPC classification number: C07D403/12 , A61K31/506 , A61K45/06 , A61N5/10 , C07D403/04 , C07D471/04 , C07D487/04
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
Abstract translation: 胺取代的反向嘧啶化合物及其形式,其抑制B细胞特异性莫洛尼鼠白血病病毒整合位点1(Bmi-1)蛋白的功能和水平降低,以及用于抑制Bmi-1功能并降低其水平的方法 本文描述了用于治疗由Bmi-1介导的癌症的Bmi-1。
-
3.
公开(公告)号:ES2821529T3
公开(公告)日:2021-04-26
申请号:ES13857326
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD
IPC: C07D403/12 , A61K31/506 , A61P35/00 , C07D403/04 , C07D471/04 , C07D487/04
Abstract: Un compuesto de Fórmula (III): **(Ver fórmula)** o una forma del mismo, en donde R1 es heteroarilo bicíclico o heterociclilo bicíclico sustituido, en un miembro del anillo de átomos de carbono, con un, dos, tres o cuatro sustituyentes R5, o en un miembro del anillo de átomos de nitrógeno, con un sustituyente de átomo de oxígeno para formar un N-óxido; R3 es halo, hidrógeno, ciano, alquilo C1-8, amino, alquil C1-8-amino o (alquil C1-8)2-amino; R4 es fenilo, opcionalmente sustituido con un, dos, tres o cuatro sustituyentes R6; R5 se selecciona independientemente entre halo, alquilo C1-8, ciano, hidroxilo, nitro, oxo, ciano-alquilo C1-8, halo alquilo C1-8, hidroxil-alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, halo-alcoxi C1-8, alquenilo C2-8, alcoxi C1-8- alquenilo C2-8, alquinilo C2-8, alcoxi C1-8-alquinilo C2-8, carboxilo, amino, alquil C1-8-amino, (alquil C1-8)2-amino, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, (alquil C1-8)2-amino-alquilo C1-8, hidroxil-alquil C1-8-amino, hidroxilalquil C1-8-amino-alquilo C1-8, hidroxil-alquil C1-8-amino-alquilo C1-8-amino, alquil C1-8-tio, alquil C1-8-carbonilo, alquil C1-8-carbonil-amino, alquil C1-8-carbonil-oxi, alquil C1-8-carbonil-oxi-alquilo C1-8, alcoxi C1-8-carbonilo, alcoxi C1-8- carbonil-alquilo C1-8, alcoxi C1-8-carbonil-amino, alquil C1-8-sulfonilo, cicloalquilo C3-14, arilo, aril-alquilo C1-8, arilamino, aril-alquil C1-8-amino, heteroarilo, heteroaril-alquilo C1-8 o heterociclilo, en donde cicloalquilo C3-14, arilo, heteroarilo o heterociclilo, y las porciones de arilo y heteroarilo de aril-alquilo C1-8, aril-amino, aril-alquil C1-8-amino y heteroaril-alquilo C1-8 están cada uno opcionalmente sustituido con un, dos, tres o cuatro sustituyentes halo, alquilo C1-8, halo-alquilo C1-8, hidroxil-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, hidroxil-alcoxi C1-8o carboxilo; R6 se selecciona independientemente entre halo-alquilo C1-8, ciano, halo, nitro, alquilo C1-8, hidroxil-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, alquenilo C2-8, alcoxi C1-8-alquenilo C2-8, alquinilo C2-8, alcoxi C1-8-alquinilo C2-8, carboxilo, formilo, formil-oxi, alquil C1-8-carbonilo, halo-alquil C1-8-carbonilo, alquil C1-8-tio, halo-alquil C1-8-tio, amino, alquil C1-8-amino, (alquil C1-8)2-amino, alquil C1-8-carbonilo, alquil C1-8-carbonil-oxi, alquil C1-8-carbonil-oxi-alquilo C1- 8, alcoxi C1-8-carbonilo, halo-alcoxi C1-8-carbonilo, alcoxi C1-8-carbonil-alquilo C1-8, alcoxi C1-8-carbonil-amino, alcoxi C1-8-carbonil-amino-alquilo C1-8, amino-carbonilo, alquil C1-8-amino-carbonilo, (alquil C1-8)2-amino-carbonilo, alquil C1-8-carbonil-amino, alquil C1-8-carbonil-amino-alquilo C1-8, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, (alquil C1-8)2-amino-alquilo C1-8, amino-alquil C1-8-amino, alquil C1-8-amino-alquil C1-8-amino, (alquil C1-8)2-amino-alquil C1- 8-amino, hidroxil-alquil C1-8-amino, hidroxil-alquil C1-8-amino-alquilo C1-8, hidroxil-alquil C1-8-amino-alquilo C1-8- amino, imino-alquilo C1-8, hidroxil-imino-alquilo C1-8, alcoxi C1-8-imino-alquilo C1-8, alquil C1-8-sulfonilo, halo-alquil C1-8-sulfonilo, amino-sulfonilo, alquil C1-8-amino-sulfonilo, (alquil C1-8)2-amino-sulfonilo, B(OR8)2, cicloalquilo C3-14, heterociclil-arilo o heteroarilo, en donde cicloalquilo C3-14, heterociclilo, arilo y heteroarilo están cada uno opcionalmente sustituido con un, dos, tres o cuatros sustituyentes halo o alquilo C1-8; y R8 es independientemente hidrógeno o alquilo C1-8; R9 y R10 son hidrógeno; en donde la forma del compuesto se selecciona entre un ácido libre, una base libre, una sal, un éster, un hidrato, un solvato, un quelato, un clatrato, un polimorfo, un isotopólogo, un estereoisómero, un racemato, un enantiómero, un diastereoisómero o un tautómero del mismo.
-
公开(公告)号:AU2018271277B2
公开(公告)日:2020-07-16
申请号:AU2018271277
申请日:2018-11-27
Applicant: PTC THERAPEUTICS INC
Inventor: DU WU , BAIAZITOV RAMIL , LEE CHANG-SUN , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D239/48
Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-
公开(公告)号:NZ708909A
公开(公告)日:2019-11-29
申请号:NZ70890913
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: DU WU , WILDE RICHARD , LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN , REN HONGYU , SYDORENKO NADIYA
IPC: C07D239/50 , A61K31/4184 , A61K31/506 , A61P35/00 , A61P35/02 , A61P35/04 , C07D235/04
Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein. 4,6-diamino-pyrimidine compounds of Formula (I) are described, wherein R1 is substituted 1H-benzimidazolyl, X is N, R2 is amino and the remaining substituents are as defined herein.
-
公开(公告)号:HK1215032A1
公开(公告)日:2016-08-12
申请号:HK16103069
申请日:2016-03-16
Applicant: PTC THERAPEUTICS INC
Inventor: LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D20060101
-
公开(公告)号:PE20151413A1
公开(公告)日:2015-10-23
申请号:PE2015000665
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: DU WU , SYDORENKO NADIYA , BAIAZITOV RAMIL , REN HONGYU , DAVIS THOMAS W , PAGET STEVEN D , MOON YOUNG-CHOON , CAO LIANGXIAN , LEE CHANG-SUN , LIU RONGGANG , WILDE RICHARD
IPC: C07D239/48
Abstract: Referido a derivados de pirimidina sustituida con amina de formula (I) y formas de la misma que inhiben la funcion y reducen el nivel de la proteina del sitio de integracion 1 (Bmi-1) del virus de la leucemia de Moloney especifico de celulas B su uso para inhibir la funcion de Bmi-1 y reducir el nivel de Bmi-1 en el tratamiento de un cancer mediado por Bmi-1. Donde R1 es heteroarilo, etc; R2 es H, CN, etc; R3 es H, CN, etc. R4 es cicloalquilo, etc. Los compuestos preferidos son: N-(4-metoxifenil)-2-(2-metil-1H-bencimidazol-1-il)pirimidin-4-amina; N-(2,3-dihidro-1,4-benzodioxin-6-il)-2-(2-metilimidazo[1,2-a]piridin-3-il)pirimidin-4-amina; entre otros
-
公开(公告)号:CA2922657C
公开(公告)日:2022-04-12
申请号:CA2922657
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: DU WU , BAIAZITOV RAMIL , LEE CHANG-SUN , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D403/04 , A61K31/506 , A61P35/00 , C07D401/04 , C07D413/04 , C07D471/04
Abstract: Amine substituted pyrimidine compounds, including compound of formula (I): (see formula I) and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1.
-
公开(公告)号:PL2922828T3
公开(公告)日:2020-12-28
申请号:PL13857326
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: PAGET STEVEN D , REN HONGYU , LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC: C07D403/12 , A61K31/506 , A61P35/00 , C07D403/04 , C07D471/04 , C07D487/04
-
公开(公告)号:NZ718055A
公开(公告)日:2020-01-31
申请号:NZ71805513
申请日:2013-11-21
Applicant: PTC THERAPEUTICS INC
Inventor: DU WU , WILDE RICHARD , BAIAZITOV RAMIL , PAGET STEVEN , REN HONGYU , SYDORENKO NADIYA , LEE CHANG-SUN , MOON YOUNG-CHOON
IPC: C07D239/48
Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B -cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein. Compounds of Formula (I) are described, wherein X, R1, R2, R3 and R4 are as defined herein.
-
-
-
-
-
-
-
-
-